类风湿关节炎患者对利妥昔单抗无应答与B细胞受体库破坏不完全相关
该研究采用基于RNA的下一代测序分析24例血清阳性类风湿关节炎患者接受利妥昔单抗治疗前后外周血和滑膜组织的B细胞受体(BCR)库。治疗后4周外周血BCR库克隆数减少、优势克隆增加且突变负荷升高,而滑膜组织BCR库至第16周才出现变化;第4周外周血优势克隆比例高且与基线克隆重叠多者,第3个月按EULAR标准评估更可能无应答。
要点
- 利妥昔单抗治疗后4周外周血BCR库即出现克隆性变化,滑膜组织变化较晚。
- 第4周外周血优势克隆比例高及与基线克隆重叠多与第3个月无应答相关。
- 早期外周血BCR库清除不彻底可能预测利妥昔单抗临床无应答。
核心结论
- 利妥昔单抗治疗后外周血BCR克隆性在4周时已发生显著变化,而滑膜组织变化出现较晚。
- 治疗第一个月内优势基线外周血BCR库清除不完全可能预测3个月时临床无应答。
研究设计与样本
- 研究纳入24例接受利妥昔单抗治疗的血清阳性类风湿关节炎患者,采用基于RNA的下一代测序分析外周血和滑膜组织样本的BCR库。
- 样本采集于治疗前、治疗后第4周及第16或24周,评估克隆扩增、突变负荷和克隆重叠,并与临床应答相关。
主要发现
- 治疗4周后外周血BCR库由更少、更具优势且突变更多的BCR克隆组成。
- 滑膜组织BCR库至治疗后第16周才检测到与基线克隆重叠减少及突变负荷增加。
- 第3个月按EULAR标准无应答者(n=5)第4周外周血优势克隆比例高于中度应答者(n=9),中位数(IQR)分别为36(27-52)和18(16-26),p<0.01。
- 无应答者第4周外周血与基线克隆重叠中位数(IQR)为5%(2%-20%),高于中度应答者的0%(0%-0%),p≤0.01。
关键数值与推荐
- 临床应答采用欧洲抗风湿病联盟(EULAR)应答标准评估。
- 无应答者第4周外周血优势克隆中位数(IQR)为36(27-52),中度应答者为18(16-26),p<0.01。
- 无应答者第4周外周血与基线克隆重叠中位数(IQR)为5%(2%-20%),中度应答者为0%(0%-0%),p≤0.01。
临床怎么用
- 利妥昔单抗治疗早期(4周)监测外周血BCR库特征可能有助于预测3个月临床应答。
- 优势克隆持续存在且与基线克隆重叠多提示B细胞清除不彻底,需关注无应答风险。
局限性
- 研究样本量较小,无应答者仅5例、中度应答者9例。
- 滑膜组织样本采集时间点有限,未在所有时间点同步评估外周血与滑膜组织。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To gain more insight into the dynamics of lymphocyte depletion and develop new predictors of clinical response to rituximab in rheumatoid arthritis (RA). METHODS: RNA-based next-generation sequencing was used to analyse the B cell receptor (BCR) repertoire in peripheral blood and synovial tissue samples collected from 24 seropositive patients with RA treated with rituximab. Clonal expansion, mutation load and clonal overlap were assessed in samples collected before, at week 4 and at week 16 or 24 after treatment and correlated to the patients' clinical response. RESULTS: After 4 weeks of rituximab-induced B cell depletion, the peripheral blood BCR repertoire of treated patients consisted of fewer, more dominant and more mutated BCR clones. No significant changes in the synovial tissue BCR repertoire were detected until week 16 post-treatment, when a reduced clonal overlap with baseline and an increased mutation load were observed. In patients who were non-responders at month 3 (n=5) using the European League Against Rheumatism response criteria, peripheral blood samples taken at week 4 after rituximab treatment showed more dominant clones compared with moderate responders (n=9) (median (IQR): 36 (27-52) vs 18 (16-26); p<0.01) and more clonal overlap with the baseline (median (IQR): 5% (2%-20%) vs 0% (0%-0%); p≤0.01). CONCLUSION: Significant changes in BCR clonality are observed in peripheral blood of patients 4 weeks after rituximab treatment, while changes in synovial tissue were observed at later time points. Incomplete depletion of the dominant baseline peripheral blood BCR repertoire in the first month of treatment might predict clinical non-response at 3 months.
引用
- Pollastro S, Klarenbeek PL, Doorenspleet ME, et al. Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire. Ann Rheum Dis. 2019. PMID: 31217169. doi:10.1136/annrheumdis-2018-214898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。